Kura Oncology: Funding, Investors & Team (Oct 2026)
Kura Oncology is a biopharmaceutical business in the clinical stages dedicated on achieving the potential of precision medicines for the treatment of cancer. Our small-molecule therapeutic candidates focus on signaling pathways and other cancer-causing factors since there is a compelling clinical and scientific case for doing so in order to enhance outcomes by determining which patients will respond best to treatment. Tipifarnib, a farnesyl transferase inhibitor, is presently undergoing a registration-directed clinical trial, and KO-539, a menin-MLL inhibitor, is presently through a Phase 1/2A clinical trial. Both of these drugs are in our pipeline. Please visit our website at www.kuraoncology.com for further details.
Kura Oncology has raised $275M across 2 funding rounds on record, the most recent an undisclosed round of $150M announced in Jan 2024.
That round is above the $8.1M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Kura Oncology Company Profile and Key Stats
Latest funding round on record: Jan 2024.
Kura Oncology Funding Rounds
Kura Oncology raised $125M in an undisclosed round announced in Nov 2022.
1.2 years later, an undisclosed round of $150M was announced in Jan 2024.
Kura Oncology Founders and Leadership Team
Contact details for the Kura Oncology team: 1 of 1 has an email address on file.
Start 14-day free trial →Kura Oncology Funding Compared to Other Biotechnology Startups
Kura Oncology's latest round of $150M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Kura Oncology in Biotechnology and La Jolla
Companies Similar to Kura Oncology
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Circle Pharma is a biotechnology company in the initial stages of development that uses unique computational…
Evvy is for people with vaginas who want to be empowered with information about their microbiome. Their…
Kura Oncology Funding FAQs
What does Kura Oncology do?
Kura Oncology is a biopharmaceutical business in the clinical stages dedicated on achieving the potential of precision medicines for the treatment of cancer. Our small-molecule therapeutic candidates focus on signaling pathways and other cancer-causing factors since there is a compelling clinical and scientific case for doing so in order to enhance outcomes by determining which patients will respond best to treatment. Tipifarnib, a farnesyl transferase inhibitor, is presently undergoing a registration-directed clinical trial, and KO-539, a menin-MLL inhibitor, is presently through a Phase 1/2A clinical trial. Both of these drugs are in our pipeline. Please visit our website at www.kuraoncology.com for further details.
How much funding has Kura Oncology raised?
Kura Oncology has raised $275M across 2 rounds on record. The most recent is an undisclosed round of $150M announced in Jan 2024.
When did Kura Oncology last raise funding?
Kura Oncology's most recent funding round on record is an undisclosed round of $150M, announced in Jan 2024.
Who founded Kura Oncology?
FundedIQ lists Troy Wilson (Founder) at Kura Oncology.
Where is Kura Oncology headquartered?
Kura Oncology is based in La Jolla, California, United States.
How many employees does Kura Oncology have?
Kura Oncology is in the 101-250 employee band.
How does Kura Oncology's funding compare to other Biotechnology startups?
Kura Oncology's latest round of $150M is above the $8.1M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Kura Oncology Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Kura Oncology is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.